Subscribe
Nathan Devery / Shutterstock.com
22 April 2025NewsEuropeSarah Speight

South Korean firm sues in UK over CRISPR/Cas9 blood disorder drug

Gene editing company ToolGen “seeks fair licensing agreement” for alleged infringement by rival | High-value sickle cell treatment CASGEVY was “born from ToolGen’s proprietary CRISPR RNP tech” says complaint | Potter Clarkson instructed.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Europe
‘It’s business as usual’: ERS Genomics enjoys new EPO patent after CRISPR gambit pays off
27 February 2025   The licensing company’s CEO and GC accept that ‘tactical retreats and tactical gains’ are baked into the high-profile portfolio’s future, finds Marisa Woutersen.
Biotechnology
Vertex signs $100m CRISPR deal to use sickle cell treatment
14 December 2023   Biotech firm agrees licence deal days after its gene editing treatment gets landmark FDA approval | Patents owned by the Broad Institute protect technology sold via Editas Medicines.


Editor's picks

Smart ringleader: Could Ōura’s market dominance be under threat?
Americas
Smart ringleader: Could Ōura’s market dominance be under threat?
5 September 2025

Editor's picks

Americas
Smart ringleader: Could Ōura’s market dominance be under threat?
5 September 2025
Europe
Sandoz blocked by UK court from seeking Xarelto profits
2 September 2025
Europe
UPC sees rising small molecule litigation with Pfizer in the hot seat
29 August 2025
Europe
Astellas win strengthens blockbuster drug's European position
20 August 2025
Europe
Four firms reach highest tier in WIPR’s 2025 Global Trade Secrets Rankings
18 August 2025
Americas
Latham steps into dispute over $6bn treatment, replacing Kirkland
13 August 2025

More on this story

Europe
‘It’s business as usual’: ERS Genomics enjoys new EPO patent after CRISPR gambit pays off
27 February 2025   The licensing company’s CEO and GC accept that ‘tactical retreats and tactical gains’ are baked into the high-profile portfolio’s future, finds Marisa Woutersen.
Biotechnology
Vertex signs $100m CRISPR deal to use sickle cell treatment
14 December 2023   Biotech firm agrees licence deal days after its gene editing treatment gets landmark FDA approval | Patents owned by the Broad Institute protect technology sold via Editas Medicines.

More on this story

Europe
‘It’s business as usual’: ERS Genomics enjoys new EPO patent after CRISPR gambit pays off
27 February 2025   The licensing company’s CEO and GC accept that ‘tactical retreats and tactical gains’ are baked into the high-profile portfolio’s future, finds Marisa Woutersen.
Biotechnology
Vertex signs $100m CRISPR deal to use sickle cell treatment
14 December 2023   Biotech firm agrees licence deal days after its gene editing treatment gets landmark FDA approval | Patents owned by the Broad Institute protect technology sold via Editas Medicines.

More features

GSK escalates mRNA COVID-19 vaccine dispute
Smart ringleader: Could Ōura’s market dominance be under threat?
The flaw that landed Sanofi a win in the rare disease space
Roche resolves cancer test dispute with Stanford affiliated startup
Why Masimo’s ‘rare’ move pushes Apple case into uncharted territory
UK firm expands in Germany with more litigation hires
Sandoz blocked by UK court from seeking Xarelto profits
An update on patenting in Ukraine, Russia and Eurasia